Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Pembrolizumab
Synonyms
Therapy Description

Keytruda (pembrolizumab) is an antibody against PD-1 that activates T-cell mediated anti-tumor immune response (PMID: 25977344). Keytruda (pembrolizumab) is approved in melanoma, SCLC, HNSCC, classical Hodgkin Lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, HCC, Merkel cell carcinoma, NMIBC, cutaneous SCC, MSI-H or dMMR or TMB high advanced solid tumors, NSCLC and CD274 (PD-L1)-expressing NSCLC, esophageal SCC, cervical cancer, and TNBC, in combination with platnum-based chemotherapy in NSCLC, with pemetrexed and platinum in non-squamous NSCLC with no EGFR or ALK mutations, with carboplatin and paclitaxel/nab-paclitaxel in squamous NSCLC, with axitinib or lenvatinib in RCC, with Lenvatinib in endometrial carcinoma that is not MSI-H or dMMR, in combination with platinum and fluoropyrimidine-based chemotherapy for patients with esophageal or gastroesophageal carcinoma, in combination with Herceptin (trastuzumab), fluoropyrimidine- and platinum-containing chemotherapy for CD274 (PD-L1)-positive, HER2-positive gastric or GEJ adenocarcinoma, in combination with fluoropyrimidine- and platinum-containing chemotherapy for HER2-negative gastric or GEJ adenocarcinoma, in combination with platinum-based chemotherapy, with or without bevacizumab, for patients with CD274 (PD-L1)-expressing (CPS>=1) cervical cancer, in combination with gemcitabine and cisplatin for biliary tract cancer, and in combination with chemoradiation for cervical cancer (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Pembrolizumab Keytruda MK-3475 Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 117 Keytruda (pembrolizumab) is an antibody against PD-1 that activates T-cell mediated anti-tumor immune response (PMID: 25977344). Keytruda (pembrolizumab) is approved in melanoma, SCLC, HNSCC, classical Hodgkin Lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, HCC, Merkel cell carcinoma, NMIBC, cutaneous SCC, MSI-H or dMMR or TMB high advanced solid tumors, NSCLC and CD274 (PD-L1)-expressing NSCLC, esophageal SCC, cervical cancer, and TNBC, in combination with platnum-based chemotherapy in NSCLC, with pemetrexed and platinum in non-squamous NSCLC with no EGFR or ALK mutations, with carboplatin and paclitaxel/nab-paclitaxel in squamous NSCLC, with axitinib or lenvatinib in RCC, with Lenvatinib in endometrial carcinoma that is not MSI-H or dMMR, in combination with platinum and fluoropyrimidine-based chemotherapy for patients with esophageal or gastroesophageal carcinoma, in combination with Herceptin (trastuzumab), fluoropyrimidine- and platinum-containing chemotherapy for CD274 (PD-L1)-positive, HER2-positive gastric or GEJ adenocarcinoma, in combination with fluoropyrimidine- and platinum-containing chemotherapy for HER2-negative gastric or GEJ adenocarcinoma, in combination with platinum-based chemotherapy, with or without bevacizumab, for patients with CD274 (PD-L1)-expressing (CPS>=1) cervical cancer, in combination with gemcitabine and cisplatin for biliary tract cancer, and in combination with chemoradiation for cervical cancer (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
BRAF V600E lung non-small cell carcinoma not predictive Pembrolizumab Clinical Study - Cohort Actionable In a retrospective analysis, non-small cell lung cancer patients harboring BRAF V600E did not demonstrate a significantly different response to treatment with either Keytruda (pembrolizumab), Opdivo (nivolumab), or Tecentriq (atezolizumab), compared to patients with BRAF non-V600E mutations, demonstrating an objective response rate of 25% (3/12) vs 33% (3/9) (p=1.0) and median progression-free survival of 3.7 months vs 4.1 months (p=0.37) (PMID: 29723688). 29723688
MSH6 negative thyroid gland medullary carcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines for patients with medullary thyroid carcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) after progression on prior treatment (NCCN.org). detail...
MLH1 negative thyroid gland papillary carcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines for patients with papillary thyroid carcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) after progression on prior treatment (NCCN.org). detail...
MSH6 negative vaginal carcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as preferred second-line or subsequent therapy for patients with recurrent or metastatic vaginal squamous cell carcinoma or adenocarcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MSH6 negative Squamous Cell Carcinoma of Unknown Primary sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines for patients with squamous cell carcinoma of unknown primary with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
ALK rearrange lung non-small cell carcinoma no benefit Pembrolizumab Guideline Actionable Immune checkpoint inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), Tecentriq (atezolizumab), and Imfinzi (durvalumab) are not indicated for use as subsequent therapy in non-small cell lung cancer patients with ALK rearrangement (NCCN.org). detail...
ALK rearrange lung non-small cell carcinoma no benefit Pembrolizumab Clinical Study - Cohort Actionable In a retrospective analysis, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694). 27225694
MLH1 negative vaginal carcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as preferred second-line or subsequent therapy for patients with recurrent or metastatic vaginal squamous cell carcinoma or adenocarcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MLH1 negative Ewing sarcoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as systemic therapy for metastatic Ewing sarcoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MLH1 negative ovarian germ cell cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as recurrence therapy for patients with malignant ovarian germ cell tumors with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MLH1 negative pancreatic cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as second or later-line therapy for patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) pancreatic cancer (PMID: 37678671; ESMO.org). 37678671 detail...
MLH1 negative pancreatic cancer sensitive Pembrolizumab Phase II Actionable In a Phase II trial (KEYNOTE-158), Keytruda (pembrolizumab) treatment resulted in an objective response rate of 18.2% (4/22, 1 complete response and 3 partial responses), a duration of response that was not reached, a median progression-free survival of 2.1 mo, and a median overall survival of 3.7 mo in pancreatic cancer patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 35680043; NCT02628067). 35680043
MLH1 negative small intestine adenocarcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as an initial therapy for patients with advanced or metastatic small bowel adenocarcinoma with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MSH6 negative sarcoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as systemic therapy for soft tissue sarcoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC), regardless of sarcoma sub-type (NCCN.org). detail...
MSH6 negative endometrial cancer sensitive Pembrolizumab Guideline Actionable Immune checkpoint inhibitor monotherapy including Keytruda (pembrolizumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org). detail... 36696825
MSH6 negative endometrial cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org). detail... 35690222
MLH1 negative endometrial cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org). 35690222 detail...
MLH1 negative endometrial cancer sensitive Pembrolizumab Guideline Actionable Immune checkpoint inhibitor monotherapy including Keytruda (pembrolizumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org). detail... 36696825
MLH1 negative rectum cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as a preferred primary therapy for advanced or metastatic rectum cancer patients with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MLH1 negative ovary epithelial cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as systemic therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MSH6 negative colorectal cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as first-line therapy for patients with metastatic colorectal cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 36307056; ESMO.org). 36307056 detail...
MSH6 negative colorectal cancer sensitive Pembrolizumab FDA approved Actionable In a Phase III (KEYNOTE-177) trial that supported FDA approval, Keytruda (pembrolizumab) treatment as first-line therapy significantly improved median progression-free survival (16.5 vs 8.2 mo, HR=0.60, p=0.0002) compared to chemotherapy in patients with advanced microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) colorectal cancer (PMID: 33264544; NCT02563002). 33264544 detail...
MSH6 negative colorectal cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) as first-line therapy for patients with advanced or metastatic colorectal cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 37236086; ESMO.org). detail... 37236086
MSH6 negative ampulla of Vater adenocarcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as first-line or subsequent therapy for metastatic ampullary adenocarcinoma patients with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MLH1 negative gastroesophageal junction adenocarcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as first-line, second-line, or subsequent therapy for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) gastroesophageal junction cancer that are unresectable, locally advanced, recurrent, or metastatic (NCCN.org). detail...
MLH1 negative osteosarcoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as systemic therapy for metastatic osteosarcoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MSH6 negative Ewing sarcoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as systemic therapy for metastatic Ewing sarcoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MLH1 negative small intestine cancer sensitive Pembrolizumab Phase II Actionable In a Phase II trial (KEYNOTE-158), Keytruda (pembrolizumab) treatment resulted in an objective response rate of 48.0% (12/25, 3 complete responses and 8 partial responses), a duration of response and a median overall survival that was not reached, and a median progression-free survival of 23.4 mo in small intestine cancer patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 35680043; NCT02628067). 35680043
MSH6 negative gallbladder cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as primary therapy and subsequent-line therapy for patients with unresectable or metastatic biliary tract cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC), including gallbladder cancer (NCCN.org). detail...
MLH1 negative biliary tract cancer sensitive Pembrolizumab Phase II Actionable In a Phase II trial (KEYNOTE-158), Keytruda (pembrolizumab) treatment resulted in an objective response rate of 40.9% (9/22, 3 complete responses and 6 partial responses), a duration of response of 30.5 mo, a median progression-free survival of 4.2 mo, and a median overall survival of 19.4 mo in biliary tract cancer patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 35680043; NCT02628067). 35680043
MSH6 negative intrahepatic cholangiocarcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as primary therapy and subsequent-line therapy for patients with unresectable or metastatic biliary tract cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC), including intrahepatic cholangiocarcinoma (NCCN.org). detail...
MSH6 negative small intestine adenocarcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as an initial therapy for patients with advanced or metastatic small bowel adenocarcinoma with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
BRAF V600E melanoma decreased response Pembrolizumab Clinical Study Actionable In a retrospective analysis, real-world treatment with either Keytruda (pembrolizumab) or Toripalimab (JS001) resulted in a median disease-free survival of 17 months in melanoma patients harboring BRAF V600E compared to 32 months in patients with wild-type BRAF, NRAS, and KIT (p=0.022) (PMID: 37403699). 37403699
BRAF V600E melanoma decreased response Pembrolizumab Clinical Study Actionable In a retrospective analysis, patients with melanoma harboring BRAF V600E (n=84) had decreased response rates (29% vs. 53%, p=0.059), progression-free survival (2.7 vs. 19 months, p=0.049), and overall survival (11.7 vs. 20.4 months, p=0.081) relative to patients with BRAF V600K (n=19) when treated with Keytruda (pembrolizumab) (n=62 and 17 for BRAF V600E and V600K, respectively) or Opdivo (nivolumab) (n=22 and 2 for BRAF V600E and V600K, respectively) (PMID: 30630828). 30630828
MLH1 negative neuroendocrine tumor sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines for patients with mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) locally advanced or metastatic well-differentiated, Grade 3 neuroendocrine tumors or unresectable or metastatic extrapulmonary poorly differentiated neuroendocrine carcinoma, large or small cell carcinoma, or mixed neuroendocrine/non-neuroendocrine neoplasms who have progressed on or following prior treatment (NCCN.org). detail...
MSH6 negative esophagus adenocarcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as first-line, second-line, or subsequent therapy for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) esophageal adenocarcinoma that are unresectable, locally advanced, recurrent, or metastatic (NCCN.org). detail...
MLH1 negative pancreatic adenocarcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as first-line or subsequent therapy for patients with locally advanced, metastatic, or recurrent pancreatic adenocarcinoma with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MLH1 negative ovarian cancer sensitive Pembrolizumab Phase II Actionable In a Phase II trial (KEYNOTE-158), Keytruda (pembrolizumab) treatment resulted in an objective response rate of 33.3% (8/24, 3 complete responses and 5 partial responses), a duration of response that was not reached, a median progression-free survival of 2.2 mo, and a median overall survival of 33.6 mo in ovarian cancer patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 35680043; NCT02628067). 35680043
MSH6 negative bone cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as a systemic therapy for patients with unresectable or metastatic bone cancer with high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MLH1 negative Adenocarcinoma of Unknown Primary sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines for patients with adenocarcinoma of unknown primary with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MLH1 negative gallbladder cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as primary therapy and subsequent-line therapy for patients with unresectable or metastatic biliary tract cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC), including gallbladder cancer (NCCN.org). detail...
MSH6 negative extrahepatic bile duct carcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as primary therapy and subsequent-line therapy for patients with unresectable or metastatic biliary tract cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC), including extrahepatic cholangiocarcinoma (NCCN.org). detail...
MSH6 negative Advanced Solid Tumor sensitive Pembrolizumab FDA approved Actionable In a combined analysis of 5 trials that supported FDA approval, Keytruda (pembrolizumab) therapy resulted in an objective response rate of 39.6% (59/149) in advanced solid tumor patients with high levels of microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 30787022; NCT01876511, NCT02460198, NCT01848834, NCT02054806, NCT02628067). detail... 30787022
MLH1 negative endometrial carcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as first-line or subsequent-line therapy for patients with recurrent or metastatic endometrial carcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MLH1 negative endometrial carcinoma sensitive Pembrolizumab FDA approved - On Companion Diagnostic Actionable In a Phase II trial (KEYNOTE-158) that supported FDA approval, Keytruda (pembrolizumab) treatment resulted in an objective response rate of 48% (38/79, 11 complete responses, 27 partial responses) in patients with advanced microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial carcinoma, with a median progression-free survival of 13.1 months (PMID: 34990208; NCT02628067). detail... 34990208 detail...
KIT exon11 melanoma not predictive Pembrolizumab Clinical Study Actionable In a retrospective analysis, real-world treatment with either Keytruda (pembrolizumab) or Toripalimab (JS001) resulted in a median disease-free survival of 33 months in melanoma patients harboring KIT mutations in either exon 11 (64.8%), exon 13 (17.6%), or exon 17 (17.6%) compared to 32 months in patients with wild-type BRAF, NRAS, and KIT (p=0.200) (PMID: 37403699). 37403699
MSH6 negative esophagus squamous cell carcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as second-line or subsequent therapy for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) esophageal squamous cell carcinoma that are unresectable, locally advanced, recurrent, or metastatic (NCCN.org). detail...
MLH1 negative chordoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as systemic therapy for metastatic chordoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
KIT exon13 melanoma not predictive Pembrolizumab Clinical Study Actionable In a retrospective analysis, real-world treatment with either Keytruda (pembrolizumab) or Toripalimab (JS001) resulted in a median disease-free survival of 33 months in melanoma patients harboring KIT mutations in either exon 11 (64.8%), exon 13 (17.6%), or exon 17 (17.6%) compared to 32 months in patients with wild-type BRAF, NRAS, and KIT (p=0.200) (PMID: 37403699). 37403699
MSH6 negative biliary tract cancer sensitive Pembrolizumab Phase II Actionable In a Phase II trial (KEYNOTE-158), Keytruda (pembrolizumab) treatment resulted in an objective response rate of 40.9% (9/22, 3 complete responses and 6 partial responses), a duration of response of 30.5 mo, a median progression-free survival of 4.2 mo, and a median overall survival of 19.4 mo in biliary tract cancer patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 35680043; NCT02628067). 35680043
IDH1 wild-type PTEN mut glioblastoma resistant Pembrolizumab Clinical Study - Cohort Actionable In a retrospective analysis, PTEN mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who did not respond to anti-PD-1 therapy, with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who responded (odds ratio=0.85, p=0.0063), with 23 PTEN mutations identified in 32 non-responders and 3 in 13 responders (PMID: 30742119). 30742119
MSH6 negative neuroendocrine tumor sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines for patients with mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) locally advanced or metastatic well-differentiated, Grade 3 neuroendocrine tumors or unresectable or metastatic extrapulmonary poorly differentiated neuroendocrine carcinoma, large or small cell carcinoma, or mixed neuroendocrine/non-neuroendocrine neoplasms who have progressed on or following prior treatment (NCCN.org). detail...
MSH6 negative prostate adenocarcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as a second-line therapy for patients with advanced or metastatic prostate adenocarcinoma with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MSH6 negative endometrial carcinoma sensitive Pembrolizumab FDA approved - On Companion Diagnostic Actionable In a Phase II trial (KEYNOTE-158) that supported FDA approval, Keytruda (pembrolizumab) treatment resulted in an objective response rate of 48% (38/79, 11 complete responses, 27 partial responses) in patients with advanced microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial carcinoma, with a median progression-free survival of 13.1 months (PMID: 34990208; NCT02628067). detail... detail... 34990208
MSH6 negative endometrial carcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as first-line or subsequent-line therapy for patients with recurrent or metastatic endometrial carcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MLH1 negative esophagus adenocarcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as first-line, second-line, or subsequent therapy for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) esophageal adenocarcinoma that are unresectable, locally advanced, recurrent, or metastatic (NCCN.org). detail...
MSH6 negative ovary epithelial cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as systemic therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MSH6 negative Adenocarcinoma of Unknown Primary sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines for patients with adenocarcinoma of unknown primary with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MSH6 negative cholangiocarcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as second or late-line therapy for patients with cholangiocarcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 36372281; ESMO.org). detail... 36372281
MSH6 negative ovarian germ cell cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as recurrence therapy for patients with malignant ovarian germ cell tumors with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MLH1 negative ampulla of Vater adenocarcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as first-line or subsequent therapy for metastatic ampullary adenocarcinoma patients with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MLH1 negative Advanced Solid Tumor sensitive Pembrolizumab FDA approved Actionable In a combined analysis of 5 trials that supported FDA approval, Keytruda (pembrolizumab) therapy resulted in an objective response rate of 39.6% (59/149) in advanced solid tumor patients with high levels of microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 30787022; NCT01876511, NCT02460198, NCT01848834, NCT02054806, NCT02628067). detail... 30787022
NRAS mutant melanoma predicted - sensitive Pembrolizumab Clinical Study - Cohort Actionable In a clinical study, NRAS mutations were associated with higher 6-month objective response rate (53.3% vs. 19.6% without NRAS mutations; p=0.019) following treatment with Keytruda (pembrolizumab) or Opdivo (nivolumab) in patients with metastatic melanoma, however, progression-free survival and overall survival were similar between patients with and without NRAS mutations (PMID: 29973670). 29973670
MLH1 negative penile cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as subsequent-line systemic therapy for metastatic/recurrent penile cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MLH1 negative extrahepatic bile duct carcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as primary therapy and subsequent-line therapy for patients with unresectable or metastatic biliary tract cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC), including extrahepatic cholangiocarcinoma (NCCN.org). detail...
MLH1 negative thyroid gland medullary carcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines for patients with medullary thyroid carcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) after progression on prior treatment (NCCN.org). detail...
MSH6 negative testicular germ cell cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as a third-line therapy for metastatic testicular germ cell cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
JAK2 inact mut melanoma predicted - resistant Pembrolizumab Case Reports/Case Series Actionable In a clinical study, a melanoma patient treated with Keytruda (pembrolizumab) initially demonstrated a partial response, however, post 734 days developed disease progression due to a splice site mutation in JAK2, which resulted in an intron inclusion and an early stop codon, leading to a loss of protein expression (PMID: 27433843). 27433843
MLH1 negative testicular germ cell cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as a third-line therapy for metastatic testicular germ cell cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
BRAF V600K melanoma predicted - sensitive Pembrolizumab Clinical Study - Cohort Actionable In a retrospective analysis, patients with melanoma harboring BRAF V600K (n=19) had increased tumor mutational burden and greater response rates (53% vs. 29%, p=0.059), progression-free survival (19 vs. 2.7 months, p=0.049), and overall survival (20.4 vs. 11.7 months, p=0.081) relative to patients with BRAF V600E (n=84) when treated with Keytruda (pembrolizumab) (n=17 and 62 for BRAF V600K and V600E, respectively) or Opdivo (nivolumab) (n=2 and 22 for BRAF V600K and V600E, respectively) (PMID: 30630828). 30630828
MLH1 negative thyroid gland follicular carcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines for patients with follicular thyroid carcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) after progression on prior treatment (NCCN.org). detail...
MLH1 negative Squamous Cell Carcinoma of Unknown Primary sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines for patients with squamous cell carcinoma of unknown primary with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MLH1 negative intrahepatic cholangiocarcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as primary therapy and subsequent-line therapy for patients with unresectable or metastatic biliary tract cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC), including intrahepatic cholangiocarcinoma (NCCN.org). detail...
MSH6 negative thyroid gland Hurthle cell carcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines for patients with Hurthle cell thyroid carcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) after progression on prior treatment (NCCN.org). detail...
MLH1 negative stomach cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as second-line therapy for patients with advanced or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) gastric cancer (PMID: 35914639; ESMO.org). 35914639 detail...
MLH1 negative stomach cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as first-line, second-line, or subsequent therapy for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) stomach cancer that are unresectable, locally advanced, recurrent, or metastatic (NCCN.org). detail...
MLH1 negative stomach cancer sensitive Pembrolizumab Phase II Actionable In a Phase II trial (KEYNOTE-158), Keytruda (pembrolizumab) treatment resulted in an objective response rate of 31.0% (13/42, 4 complete responses and 9 partial responses), a duration of response that was not reached, a median progression-free survival of 3.2 mo, and a median overall survival of 11.0 mo in gastric cancer patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 35680043; NCT02628067). 35680043
MSH6 negative thyroid gland follicular carcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines for patients with follicular thyroid carcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) after progression on prior treatment (NCCN.org). detail...
MSH6 negative pancreatic adenocarcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as first-line or subsequent therapy for patients with locally advanced, metastatic, or recurrent pancreatic adenocarcinoma with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MLH1 negative Cancer of Unknown Primary sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as second-line therapy for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) cancer of unknown primary (CUP), or as first-line therapy for patients with MSI-H or dMMR colon-like CUP (PMID: 36563965; ESMO.org). detail... 36563965
KIT exon17 melanoma not predictive Pembrolizumab Clinical Study Actionable In a retrospective analysis, real-world treatment with either Keytruda (pembrolizumab) or Toripalimab (JS001) resulted in a median disease-free survival of 33 months in melanoma patients harboring KIT mutations in either exon 11 (64.8%), exon 13 (17.6%), or exon 17 (17.6%) compared to 32 months in patients with wild-type BRAF, NRAS, and KIT (p=0.200) (PMID: 37403699). 37403699
FBXW7 R505C melanoma predicted - resistant Pembrolizumab Case Reports/Case Series Actionable In a clinical case study, a melanoma patient treated with Keytruda (pembrolizumab) demonstrated a response in all lesions except one, which was found to harbor FBXW7 R505C (PMID: 32371478). 32371478
MSH6 negative colon cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as preferred primary or subsequent therapy for patients with advanced or metastatic colon cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MSH6 negative penile cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as subsequent-line systemic therapy for metastatic/recurrent penile cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MSH6 negative ovarian cancer sensitive Pembrolizumab Phase II Actionable In a Phase II trial (KEYNOTE-158), Keytruda (pembrolizumab) treatment resulted in an objective response rate of 33.3% (8/24, 3 complete responses and 5 partial responses), a duration of response that was not reached, a median progression-free survival of 2.2 mo, and a median overall survival of 33.6 mo in ovarian cancer patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 35680043; NCT02628067). 35680043
MSH6 negative vulva cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as a second-line therapy for patients with MSI high or dMMR (often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) vulva cancer (NCCN.org). detail...
NRAS act mut melanoma decreased response Pembrolizumab Clinical Study Actionable In a retrospective analysis, real-world treatment with either Keytruda (pembrolizumab) or Toripalimab (JS001) resulted in a median disease-free survival of 9 months in melanoma patients harboring activating NRAS mutations in either G12 (29%) or Q61 (67.1%) compared to 32 months in patients with wild-type BRAF, NRAS, and KIT (p<0.0001) (PMID: 37403699). 37403699
MLH1 negative cervical cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as preferred second-line or subsequent therapy for patients with cervical cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MLH1 negative colorectal cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as first-line therapy for patients with metastatic colorectal cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 36307056; ESMO.org). 36307056 detail...
MLH1 negative colorectal cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) as first-line therapy for patients with advanced or metastatic colorectal cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 37236086; ESMO.org). detail... 37236086
MLH1 negative colorectal cancer sensitive Pembrolizumab FDA approved Actionable In a Phase III (KEYNOTE-177) trial that supported FDA approval, Keytruda (pembrolizumab) treatment as first-line therapy significantly improved median progression-free survival (16.5 vs 8.2 mo, HR=0.60, p=0.0002) compared to chemotherapy in patients with advanced microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) colorectal cancer (PMID: 33264544; NCT02563002). 33264544 detail...
MSH6 negative gastroesophageal junction adenocarcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as first-line, second-line, or subsequent therapy for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) gastroesophageal junction cancer that are unresectable, locally advanced, recurrent, or metastatic (NCCN.org). detail...
MSH6 negative pancreatic cancer sensitive Pembrolizumab Phase II Actionable In a Phase II trial (KEYNOTE-158), Keytruda (pembrolizumab) treatment resulted in an objective response rate of 18.2% (4/22, 1 complete response and 3 partial responses), a duration of response that was not reached, a median progression-free survival of 2.1 mo, and a median overall survival of 3.7 mo in pancreatic cancer patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 35680043; NCT02628067). 35680043
MSH6 negative pancreatic cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as second or later-line therapy for patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) pancreatic cancer (PMID: 37678671; ESMO.org). detail... 37678671
BRAF mut IDH1 wild-type glioblastoma predicted - sensitive Pembrolizumab Clinical Study - Cohort Actionable In a retrospective analysis, MAPK pathway mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who responded to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who did not respond (odds ratio=12.8, p=0.019), with 4 MAPK pathway mutations (2 in BRAF, 2 in PTPN11) identified in 13 responders and 1 (BRAF) in 32 non-responders (PMID: 30742119). 30742119
MLH1 negative colon cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as preferred primary or subsequent therapy for patients with advanced or metastatic colon cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
TP53 mutant lung non-small cell carcinoma predicted - sensitive Pembrolizumab Clinical Study - Cohort Actionable In a clinical study, immune checkpoint inhibitor treatment including Keytruda (pembrolizumab) (n=1), Opdivo (nivolumab) with (n=8) or without (n=63) Yervoy (ipilimumab) resulted in improved median overall survival (18.1 vs 8.1 months, HR=0.48, p=0.04), median progression-free survival (4.5 vs 1.4 months, p=0.03), and objective response rate (51.2% vs 20.7%, p=0.01) in TP53 mutant (n=41) non-small cell lung cancer patients compared to TP53 wild-type (n=31) patients (PMID: 31097096). 31097096
TP53 mutant lung non-small cell carcinoma predicted - sensitive Pembrolizumab Clinical Study - Cohort Actionable In a clinical study, a retrospective analysis of a Phase I trial demonstrated non-small cell lung carcinoma (NSCLC) patients harboring either a TP53 mutation (n=15) or KRAS mutation (n=8) had greater progression free survival compared to NSCLC patients harboring wild-type TP53 or KRAS (n=15) (14.5mo vs 14.7mo vs 3.5mo, respectively) when treated with Keytruda (pembrolizumab) (PMID: 28039262). 28039262
MLH1 negative esophagus squamous cell carcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as first-line, second-line, or subsequent therapy for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) esophageal squamous cell carcinoma that are unresectable, locally advanced, recurrent, or metastatic (NCCN.org). detail...
BRAF mut PTEN loss melanoma no benefit Pembrolizumab Preclinical Actionable In a preclinical study, Keytruda (pembrolizumab) resulted in no benefit in a melanoma mouse model co-harboring a BRAF mutation and PTEN loss (PMID: 26645196). 26645196
MSH6 negative small intestine cancer sensitive Pembrolizumab Phase II Actionable In a Phase II trial (KEYNOTE-158), Keytruda (pembrolizumab) treatment resulted in an objective response rate of 48.0% (12/25, 3 complete responses and 8 partial responses), a duration of response and a median overall survival that was not reached, and a median progression-free survival of 23.4 mo in small intestine cancer patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 35680043; NCT02628067). 35680043
MLH1 negative prostate adenocarcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as a second-line therapy for patients with advanced or metastatic prostate adenocarcinoma cancer with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MSH6 negative chondrosarcoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as systemic therapy for metastatic chondrosarcoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MLH1 negative sarcoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as systemic therapy for soft tissue sarcoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC), regardless of sarcoma sub-type (NCCN.org). detail...
PTEN dec exp melanoma decreased response Pembrolizumab Clinical Study - Cohort Actionable In a clinical study, melanoma patients with PTEN expression in less than 10% of tumor cells demonstrated decreased response to anti-PD-1 antibodies, including Keytruda (pembrolizumab), compared to patients in which PTEN is present in over 10% of tumor cells (PMID: 26645196). 26645196
MSH6 negative stomach cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as second-line therapy for patients with advanced or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) gastric cancer (PMID: 35914639; ESMO.org). 35914639 detail...
MSH6 negative stomach cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as first-line, second-line, or subsequent therapy for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) stomach cancer that are unresectable, locally advanced, recurrent, or metastatic (NCCN.org). detail...
MSH6 negative stomach cancer sensitive Pembrolizumab Phase II Actionable In a Phase II trial (KEYNOTE-158), Keytruda (pembrolizumab) treatment resulted in an objective response rate of 31.0% (13/42, 4 complete responses and 9 partial responses), a duration of response that was not reached, a median progression-free survival of 3.2 mo, and a median overall survival of 11.0 mo in gastric cancer patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 35680043; NCT02628067). 35680043
MSH6 negative osteosarcoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as systemic therapy for metastatic osteosarcoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MLH1 negative chondrosarcoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as systemic therapy for metastatic chondrosarcoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MLH1 negative bone cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as a systemic therapy for patients with unresectable or metastatic bone cancer with high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MSH6 negative chordoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as systemic therapy for metastatic chordoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MLH1 negative thyroid gland Hurthle cell carcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines for patients with Hurthle cell thyroid carcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) after progression on prior treatment (NCCN.org). detail...
PIK3CA E545K cervical cancer predicted - sensitive Pembrolizumab Case Reports/Case Series Actionable In a clinical case study, Keytruda (pembrolizumab) treatment resulted in complete remission in a patient with metastatic cervical cancer harboring PIK3CA E545K and moderate tumor mutational burden (TMB) (9.2 mut/Mb) (PMID: 37469254). 37469254
MSH6 negative rectum cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as a preferred primary therapy for advanced or metastatic rectum cancer patients with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
MSH6 negative Cancer of Unknown Primary sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as second-line therapy for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) cancer of unknown primary (CUP), or as first-line therapy for patients with MSI-H or dMMR colon-like CUP (PMID: 36563965; ESMO.org). detail... 36563965
MLH1 negative cholangiocarcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as second or late-line therapy for patients with cholangiocarcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 36372281; ESMO.org). 36372281 detail...
MSH6 negative cervical cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as preferred second-line or subsequent therapy for patients with cervical cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). detail...
PTEN mutant gastrointestinal system cancer decreased response Pembrolizumab Clinical Study - Cohort Actionable In a retrospective analysis, patients with MSI high, dMMR gastrointestinal tumors including gastric (n=18), colorectal (n=17), cholangiocarcinoma (n=5), small intestine (n=2), pancreatic (n=2), and duodenal cancer (n=1) harboring PTEN mutations demonstrated a decreased objective response rate (21.4 vs 54.8%), overall survival (15.2 vs 25.7 mo), and progression-free survival (4.3 vs 15.6 mo) compared to PTEN-wild-type patients when treated with Keytruda (pembrolizumab) or Opdivo (nivolumab) (PMID: 33926917). 33926917
MLH1 negative vulva cancer sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as a second-line therapy for patients with MSI high or dMMR (often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) vulva cancer (NCCN.org). detail...
PTEN positive melanoma sensitive Pembrolizumab Clinical Study - Cohort Actionable In a clinical study, melanoma patients with PTEN positive tumors demonstrated a decrease in tumor size when treated with Keytruda (pembrolizumab) (PMID: 26645196). 26645196
MSH6 negative thyroid gland papillary carcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines for patients with papillary thyroid carcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) after progression on prior treatment (NCCN.org). detail...

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02132754 Phase I Pembrolizumab MK-4166 Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001) Completed 0
NCT02771197 Phase II Fludarabine + Melphalan Pembrolizumab Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant Completed USA 0
NCT03526887 Phase II Pembrolizumab Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC (Replay) Completed ESP 0
NCT02537444 Phase II Acalabrutinib Pembrolizumab ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer (KEYNOTE191) Completed USA 0
NCT02964559 Phase II Pembrolizumab Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer Active, not recruiting USA 0
NCT03694834 Phase I Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Window of Opportunity Study of Pembrolizumab in Early Stage, High Grade Obesity-driven Endometrial Cancer Terminated USA 0
NCT04462406 Phase II Pembrolizumab Nivolumab + Pembrolizumab Ipilimumab + Nivolumab Ipilimumab + Pembrolizumab Nivolumab Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial Recruiting USA 0
NCT03331731 Phase II Pembrolizumab A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma (PLIMATH) Active, not recruiting NZL | AUS 0
NCT02576990 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Primary Mediastinal Large B-cell Lymphoma (MK-3475-170/KEYNOTE-170) Completed 0
NCT03752333 Phase II Pembrolizumab Trial of Pembrolizumab in Cancer of Unknown Primary (CUPem) Active, not recruiting GBR 0
NCT03091478 Phase II Pembrolizumab Pembrolizumab in Patients With Leptomeningeal Disease Terminated USA 0
NCT03728972 Phase II Pembrolizumab Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type Active, not recruiting USA 0
NCT03428802 Phase II Pembrolizumab Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability Recruiting USA 0
NCT04987996 Phase II Pembrolizumab Belapectin + Pembrolizumab GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients Withdrawn USA 0
NCT04938609 Phase II Pembrolizumab Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC) Recruiting USA 0
NCT02684461 Phase II Pembrolizumab Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel Completed USA 0
NCT02541565 Phase I Pembrolizumab Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate Rituximab Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma Completed USA 0
NCT03004183 Phase II Pembrolizumab AdV-tk + Valacyclovir SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC (STOMP) Completed USA 0
NCT05609968 Phase III Pembrolizumab Pembrolizumab + Sacituzumab govitecan-hziy Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) >=50% (MK-3475-D46) Recruiting USA | ITA | GBR | DEU | CAN | AUS 18
NCT02362997 Phase II Pembrolizumab Pembrolizumab After ASCT for Hodgkin Lymphoma and DLBCL Completed USA 0
NCT03735290 Phase Ib/II Pembrolizumab Intuvax + Pembrolizumab A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer (ILIAD) Terminated USA 0
NCT04332874 Phase II Pembrolizumab A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg Recruiting USA 0
NCT02504372 Phase III Pembrolizumab Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091) Active, not recruiting 0
NCT04969861 Phase II NKTR-214 + Pembrolizumab Pembrolizumab BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) Terminated USA | ITA | AUT 1
NCT03316872 Phase II Pembrolizumab Study of Pembrolizumab and Radiotherapy in Liver Cancer Active, not recruiting CAN 0
NCT03279692 Phase II Pembrolizumab Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma Active, not recruiting USA 0
NCT02447003 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086) Completed 0
NCT04454528 Phase Ib/II Pembrolizumab BreastVax: Radiation Boost to Enhance Effectiveness of Immune Checkpoint Blockade Therapy in Operable Breast Cancer Recruiting USA 0
NCT03469804 Phase II Pembrolizumab Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi's Sarcoma (KAPKEY) Unknown status FRA 0
NCT03968419 Phase II Canakinumab Pembrolizumab Canakinumab + Pembrolizumab This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. (CANOPY-N) Terminated USA | NLD | FRA | ESP | DEU | CAN | BEL 5
NCT02520154 Phase II Carboplatin + Paclitaxel Pembrolizumab Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer Active, not recruiting USA 0
NCT03396471 Phase II Pembrolizumab Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary Terminated USA 0
NCT02702401 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) Completed 0
NCT03457948 Phase II Pembrolizumab Pembrolizumab + Yttrium-90 microsphere therapy Pembrolizumab and Liver-Directed Therapy in Treating Patients With Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Liver Metastases Active, not recruiting USA 0
NCT02530502 Phase Ib/II Temozolomide Pembrolizumab Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma Terminated USA 0
NCT04581382 Phase I Pembrolizumab Nivolumab Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma Active, not recruiting USA 0
NCT02467361 Phase Ib/II Nivolumab Pembrolizumab Ipilimumab Napabucasin A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers Completed USA 0
NCT04199104 Phase III Lenvatinib + Pembrolizumab Pembrolizumab A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010) (LEAP-10) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 11
NCT05987332 Phase II Dacarbazine Pembrolizumab Ipilimumab + Nivolumab Crizotinib + IDE196 IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 3
NCT02440425 Phase II Paclitaxel Pembrolizumab Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer Completed USA 0
NCT02576977 Phase III Pomalidomide Pembrolizumab Dexamethasone Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183) Terminated 0
NCT04754321 Phase I Pembrolizumab Pembrolizumab and Radiation Therapy Before and During Surgery for the Treatment of Persistent or Recurrent Head and Neck Cancer Recruiting USA 0
NCT05812807 Phase III Pembrolizumab Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab Recruiting USA 1
NCT05239728 Phase III Pembrolizumab Belzutifan + Pembrolizumab A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022) Active, not recruiting USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS 22
NCT03397654 Phase Ib/II Pembrolizumab Study of Pembrolizumab Following TACE in Primary Liver Carcinoma (PETAL) Active, not recruiting GBR 0
NCT02511184 Phase I Crizotinib Pembrolizumab Crizotinib Plus Pembrolizumab In Alk-positive Advanced Non Small Cell Lung Cancer Patients Terminated USA 0
NCT02303990 Phase I Pembrolizumab RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers Completed USA 0
NCT03361865 Phase III Epacadostat + Pembrolizumab Pembrolizumab Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 8
NCT02625961 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057) Recruiting USA | NLD | ITA | FRA | ESP | CAN 5
NCT03287817 Phase Ib/II Pembrolizumab Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma (ALEXANDER) Completed USA | GBR 0
NCT02365766 Phase Ib/II Cisplatin Pembrolizumab Gemcitabine Study of Neoadjuvant Pembrolizumab in Combination With Gemcitabine Based Therapy in Cis-eligible or -Ineligible Subjects With Urothelial Cancer Active, not recruiting USA 0
NCT04253964 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy Recruiting USA 0
NCT04241185 Phase III Pembrolizumab Cisplatin Mitomycin C Gemcitabine Fluorouracil Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) Recruiting USA | NLD | ITA | GBR | FRA | ESP | AUS 18
NCT04697576 Phase I Nivolumab Pembrolizumab Ipilimumab Intralesional Influenza Vaccine for the Treatment of Stage I, II, and IV Melanoma Recruiting USA 0
NCT03829332 Phase III Pembrolizumab Lenvatinib + Pembrolizumab Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007) Active, not recruiting USA | ITA | FRA | CAN | AUS 14
NCT03815058 Phase II Autogene cevumeran + Pembrolizumab Pembrolizumab A Study to Evaluate The Efficacy And Safety Of RO7198457 In Combination With Pembrolizumab Versus Pembrolizumab Alone In Participants With Previously Untreated Advanced Melanoma. Active, not recruiting USA | GBR | ESP | DEU | BEL | AUS 0
NCT06305767 Phase II Pembrolizumab mRNA-4157 + Pembrolizumab A Study of Pembrolizumab (MK-3475) Plus V940 in Participants With Bladder Cancer Post-Radical Resection (V940-005) Recruiting USA | FRA | ESP | DEU | CAN | AUS 3
NCT05323656 Phase II Pembrolizumab Pembrolizumab + Setanaxib A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU 1
NCT05317858 Phase III Pembrolizumab Blood-brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets Recruiting USA | CAN 1
NCT03197506 Phase II Pembrolizumab + Temozolomide Pembrolizumab Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma Suspended USA 0
NCT02637531 Phase I Pembrolizumab Eganelisib A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Unknown status USA 0
NCT02721732 Phase II Pembrolizumab Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Active, not recruiting USA 0
NCT03057613 Phase II Pembrolizumab A Study of the Addition of Pembrolizumab to Postoperative Radiotherapy in Resected High Risk Cutaneous Squamous Cell Cancer of the Head and Neck Completed USA 0
NCT05518032 Phase II Pembrolizumab Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC) Not yet recruiting USA 0
NCT05568550 Phase II Pembrolizumab Olaparib + Pembrolizumab Pembro With Radiation With or Without Olaparib Recruiting USA 0
NCT03391973 Phase II Pembrolizumab Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) (CUP) Active, not recruiting CAN 0
NCT03190213 Phase II Pembrolizumab Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma (Pembro NEC) Terminated USA 0
NCT04683679 Phase II Olaparib + Pembrolizumab Pembrolizumab A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer Recruiting USA 0
NCT02837263 Phase I Pembrolizumab PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer Completed USA 0
NCT06099782 Phase II MK-3475A Pembrolizumab A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) Recruiting USA | NZL | FRA | AUS 6
NCT03056599 Phase I Pembrolizumab Avelumab Interferon gamma Olaratumab Trabectedin Nivolumab Gemcitabine Interferon alpha-2b Doxorubicin Atezolizumab Eribulin Ipilimumab Durvalumab Aldesleukin Bortezomib Docetaxel Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma Completed USA 0
NCT05566223 Phase Ib/II Aldesleukin + CISH-inactivated autologous TILs + Cyclophosphamide + Fludarabine Pembrolizumab Phase 1/2 Study of CISH Inactivated TILs in the Treatment of NSCLC (CheckCell-2) Not yet recruiting USA 0
NCT02981914 Phase 0 Pembrolizumab Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation Completed USA 0
NCT04318717 Phase Ib/II Pembrolizumab Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma Recruiting USA 0
NCT03901378 Phase II Carboplatin + Etoposide + Pembrolizumab Pembrolizumab Cisplatin + Etoposide + Pembrolizumab Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma Withdrawn USA 0
NCT03631199 Phase III Cisplatin Paclitaxel Nab-paclitaxel Carboplatin Canakinumab + Pembrolizumab Pembrolizumab Pemetrexed Disodium Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS 31
NCT02784171 Phase II Cisplatin + Pemetrexed Disodium Pembrolizumab Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma Active, not recruiting ITA | FRA | CAN 0
NCT03761914 Phase Ib/II Galinpepimut-S Galinpepimut-S + Pembrolizumab Pembrolizumab Sargramostim Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers Active, not recruiting USA 0
NCT02528357 Phase I GSK3174998 Pembrolizumab GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors Completed USA | NLD | FRA | CAN 0
NCT06348199 Phase III Pembrolizumab Carboplatin + Pemetrexed Disodium A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer Recruiting ESP | DEU 4
NCT02999477 Phase I Pembrolizumab Nab-paclitaxel A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer Active, not recruiting USA 0
NCT02987166 Phase I Pembrolizumab HDCRT Plus Pembrolizumab in Advanced Malignancies (UVA-AM-001) Completed USA 0
NCT04701918 Phase II Pembrolizumab Pembrolizumab And Cryoablation In Urothelial Carcinoma Recruiting USA 0
NCT03813836 Phase II Pembrolizumab Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC (POPPY) Recruiting GBR 0
NCT02730546 Phase Ib/II Carboplatin + Paclitaxel Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery Completed USA 0
NCT04322643 Phase II Durvalumab Pembrolizumab Avelumab Nivolumab Atezolizumab Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma Completed USA 0
NCT02963090 Phase II Pembrolizumab + Topotecan Pembrolizumab Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer Terminated USA 0
NCT03520686 Phase III Carboplatin + Nogapendekin alfa inbakicept + Pembrolizumab + Pemetrexed Disodium Cisplatin + Nogapendekin alfa inbakicept + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Nogapendekin alfa inbakicept + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nab-paclitaxel + Nogapendekin alfa inbakicept + Pembrolizumab QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC. Active, not recruiting USA 0
NCT05430009 Phase I Pembrolizumab Phase I Trial of Feasibility and Safety of Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer Recruiting USA 0
NCT02335411 Phase II Cisplatin + Fluorouracil + Pembrolizumab Pembrolizumab A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059) Completed 0
NCT02879994 Phase II Pembrolizumab Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer Completed USA 0
NCT03277638 Phase Ib/II Pembrolizumab Laser Interstitial Thermotherapy Combined With Checkpoint Inhibitor for Recurrent Glioblastoma Recruiting USA 0
NCT03313206 Phase II Pembrolizumab Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma (IMMUQ) Recruiting FRA 0
NCT04303169 Phase Ib/II Pembrolizumab Pembrolizumab + Vibostolimab Coxsackievirus A21 + Pembrolizumab Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C) Active, not recruiting USA | ITA | FRA | AUS 2
NCT02730130 Phase II Pembrolizumab Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients Completed USA 0
NCT03395847 Phase I Pembrolizumab + Ramucirumab Pembrolizumab A Study of Pembrolizumab Monotherapy or in Combination With Other Agents in Patients With Previously Treated Advanced Gastroesophageal Adenocarcinoma Completed USA 0
NCT03620019 Phase II Denosumab + Pembrolizumab Pembrolizumab Denosumab + Pembrolizumab in Patients With Stage IV Melanoma Completed USA 0
NCT04977375 Phase Ib/II Pembrolizumab Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma Recruiting USA 0
NCT04061590 Phase II Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Withdrawn USA 0
NCT03065400 Phase II Pembrolizumab PD-1 Inhibition in Advanced Myeloproliferative Neoplasms Completed USA 0
NCT02325557 Phase Ib/II Pembrolizumab ADXS31-142 ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046 Completed USA 0
NCT06295809 Phase II Pembrolizumab mRNA-4157 + Pembrolizumab A Study of (Neo)Adjuvant V940 and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) Recruiting AUS 1
NCT04104893 Phase II Pembrolizumab A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation (CHOMP) Recruiting USA 0
NCT05101070 Phase Ib/II Pembrolizumab + S-531011 Pembrolizumab S-531011 S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors (aCCeleR8-001) Recruiting USA 1
NCT02301039 Phase II Pembrolizumab A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas Completed USA 0
NCT03978624 Phase II Pembrolizumab Entinostat + Pembrolizumab Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer Active, not recruiting USA 0
NCT03914612 Phase III Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer Active, not recruiting USA | CAN 3
NCT05913388 Phase II Pembrolizumab GB1211 + Pembrolizumab GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma Recruiting USA 0
NCT04712851 Phase II Pembrolizumab Pembrolizumab for the Treatment of High-Grade Vulvar, Vaginal, or Cervical Intraepithelial Neoplasia Recruiting USA 0
NCT03661723 Phase II Bevacizumab Pembrolizumab Bevacizumab + Pembrolizumab Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma Active, not recruiting USA 0
NCT02332980 Phase II Pembrolizumab A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma Completed USA 0
NCT06170788 Phase III Pembrolizumab + SKB264 Pembrolizumab MK-2870 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) >= 50% (MK-2870-007) Recruiting USA | NLD | ITA | FRA | ESP | AUS 7
NCT05775289 Phase II Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + RO7247669 Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Pemetrexed Disodium + RO7247669 Carboplatin + Pemetrexed Disodium + RO7247669 RO7247669 A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS 4
NCT03036488 Phase III Cyclophosphamide + Epirubicin Cyclophosphamide + Doxorubicin Pembrolizumab Carboplatin + Paclitaxel Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 13
NCT02494583 Phase III Capecitabine Cisplatin + Fluorouracil Pembrolizumab Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) Completed 0
NCT05980000 Phase II Pembrolizumab + Ramucirumab Pembrolizumab Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma (Rambro2) Recruiting USA 0
NCT04602377 Phase II Pembrolizumab Cisplatin + Cyclophosphamide + Doxorubicin + Etoposide + Pembrolizumab Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT (PembroSCCOHT) Recruiting FRA 0
NCT04671667 Phase II Cisplatin Pembrolizumab Carboplatin Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma Recruiting USA 0
NCT03241927 Phase II Pembrolizumab Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT) Terminated USA 0
NCT02287428 Phase I NeoVax Pembrolizumab Temozolomide NeoVax + Pembrolizumab + Temozolomide NeoVax + Pembrolizumab Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With MGMT Unmethylated, Newly Diagnosed GBM Recruiting USA 0
NCT05721755 Phase III Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Fluorouracil + Pembrolizumab Carboplatin + Fluorouracil + Pembrolizumab Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck Recruiting USA 0
NCT02611960 Phase II Pembrolizumab Capecitabine + Docetaxel + Gemcitabine Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122, KEYNOTE-122) Completed 0
NCT02591615 Phase II Pembrolizumab Carboplatin + Paclitaxel Carboplatin + Pemetrexed Disodium Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC Completed USA 0
NCT03988647 Phase II Pembrolizumab Phase II Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma Terminated USA 0
NCT05024318 Phase II Pembrolizumab NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma (NAPSTER) Recruiting AUS 0
NCT02674061 Phase II Pembrolizumab Efficacy and Safety Study of Pembrolizumab (MK-3475) in Women With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100) Completed 0
NCT02564263 Phase III Pembrolizumab Docetaxel + Irinotecan + Paclitaxel Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) Completed 0
NCT06119581 Phase III Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Cisplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium LY3537982 + Pembrolizumab Carboplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C (SUNRAY-01) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 18
NCT03832569 Phase II Pembrolizumab Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors Active, not recruiting USA 0
NCT02296684 Phase II Pembrolizumab Cisplatin Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma Active, not recruiting USA 0
NCT03284424 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Adults With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) (MK-3475-629/KEYNOTE-629) Completed USA | GBR | FRA | ESP | DEU | CAN | AUS 3
NCT04152863 Phase II Pembrolizumab Coxsackievirus A21 + Pembrolizumab Efficacy, Safety, and Tolerability of V937 Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011) Terminated USA | ITA | FRA | ESP | DEU | AUS 5
NCT02306850 Phase II Pembrolizumab Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma Completed USA 0
NCT04795661 Phase II Pembrolizumab Immunotherapy in MSI/dMMR Tumors in Perioperative Setting. (IMHOTEP) Active, not recruiting FRA 0
NCT02872025 Phase I Pembrolizumab Pembrolizumab in High-risk Ductal Carcinoma in Situ (DCIS) Recruiting USA 0
NCT04801966 Phase 0 Palbociclib Alpelisib Atezolizumab Vemurafenib Ribociclib Talazoparib Cobimetinib Trametinib Abemaciclib Dabrafenib Nivolumab Binimetinib Pembrolizumab Encorafenib Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study (TAILOR) Terminated AUS 0
NCT02014636 Phase I Pazopanib Pembrolizumab Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC) Completed USA | GBR 0
NCT02268825 Phase Ib/II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers Terminated USA 0
NCT06357533 Phase III Pembrolizumab AZD2936 + Datopotamab deruxtecan AZD2936 Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC >/= 50%) and Without Actionable Genomic Alterations (TROPION-Lung10) Recruiting USA | ITA | GBR | ESP | DEU | CAN | BEL | AUT | AUS 8
NCT02305186 Phase Ib/II Pembrolizumab Capecitabine Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer Unknown status USA 0
NCT05665595 Phase III Pembrolizumab MK-7684A A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) Active, not recruiting USA | NZL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 15
NCT02252042 Phase III Pembrolizumab Methotrexate Cetuximab Docetaxel Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040) Completed 0
NCT03087760 Phase II Pembrolizumab Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer Completed USA 0
NCT06345729 Phase III Pembrolizumab MK-1084 + Pembrolizumab A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) >=50% (MK-1084-004) Recruiting USA 0
NCT05229614 Phase II Pembrolizumab Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease (ICONIC) Recruiting ITA | DEU 0
NCT02767934 Phase II Pembrolizumab Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia Terminated USA 0
NCT03897881 Phase II mRNA-4157 + Pembrolizumab Pembrolizumab An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Patients With High-Risk Melanoma (KEYNOTE-942) Recruiting USA | AUS 0
NCT02768792 Phase II Pembrolizumab High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML Active, not recruiting USA 0
NCT02658279 Phase I Pembrolizumab Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype Active, not recruiting USA 0
NCT04231526 Phase II Pembrolizumab Pembrolizumab in Early Stage Colon Cancer Recruiting USA 0
NCT02853305 Phase III Pembrolizumab Carboplatin + Cisplatin + Gemcitabine Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361) Completed 0
NCT03932409 Phase I Pembrolizumab Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer (FIERCE) Recruiting USA 0
NCT03224871 Phase I Pembrolizumab Aldesleukin Nivolumab A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC. Completed USA 0
NCT02212730 Phase I Pembrolizumab A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031) Terminated 0
NCT03293680 Phase II Pembrolizumab Pembrolizumab in Elderly Patients With Advanced Lung Cancer Active, not recruiting ESP 0
NCT04624204 Phase III Pembrolizumab Cisplatin + Etoposide Cisplatin + Etoposide + Pembrolizumab Carboplatin + Etoposide Olaparib + Pembrolizumab Carboplatin + Etoposide + Pembrolizumab Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013) Recruiting USA | ITA | GBR | FRA | ESP | CAN | BEL | AUS 17
NCT03586024 Phase Ib/II Pembrolizumab Phase I/II Study of Pembrolizumab in Patients With Relapsed or Refractory Extranodal NK/T- Cell Lymphoma (ENKTL), Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas (EBV-DLBCL) Withdrawn USA 0
NCT02454179 Phase II Pembrolizumab Acalabrutinib Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma Completed USA 0
NCT03820986 Phase III Lenvatinib + Pembrolizumab Pembrolizumab Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS 9
NCT04166487 Phase II Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed Disodium Plasma-Adapted First-Line Pembro In NSCLC Active, not recruiting USA 0
NCT05733715 Phase I Pembrolizumab Lenvatinib + Pembrolizumab Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma Recruiting USA 0
NCT04387084 Phase I Durvalumab Pembrolizumab Avelumab Cemiplimab Atezolizumab Nivolumab Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy Recruiting USA 0
NCT05173987 Phase III Cisplatin + Docetaxel Carboplatin + Docetaxel Carboplatin + Paclitaxel Cisplatin + Paclitaxel Pembrolizumab Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) Active, not recruiting USA | NZL | NLD | ITA | GBR | ESP | DEU | CAN | BEL | AUS 17
NCT02500121 Phase II Pembrolizumab Testing the PD-1 Inhibitor Pembrolizumab After Initial Chemotherapy in Patients With Metastatic Bladder Cancer Completed USA 0
NCT02375672 Phase II Pembrolizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer Completed USA 0
NCT06405230 Phase Ib/II Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Dostarlimab-gxly Carboplatin + Dostarlimab-gxly + Pemetrexed Disodium Cisplatin + Dostarlimab-gxly + Pemetrexed Disodium Pembrolizumab Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Patient-derived Organoids and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC) Not yet recruiting GBR 0
NCT02608385 Phase I Pembrolizumab Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors Active, not recruiting USA 0
NCT04995094 Phase II Pembrolizumab Pembrolizumab + PGG beta-glucan Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma Withdrawn USA 0
NCT04003610 Phase II Pembrolizumab + Pemigatinib Pembrolizumab Carboplatin + Gemcitabine Pemigatinib Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) Terminated USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT 7
NCT01993719 Phase II Pembrolizumab Aldesleukin Fludarabine Cyclophosphamide Immunotherapy Using Tumor Infiltrating Lymphocytes Comparing 2 Different Conditioning Regimens for Patients With Metastatic Melanoma Completed USA 0
NCT05934448 Phase II Pembrolizumab Pembro Plus CAR T-cell Therapy in R/R in PMBCL Recruiting USA 0
NCT05578664 Phase II Pembrolizumab Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer (PE-PE) Recruiting ITA 0
NCT06045195 Phase II Pembrolizumab Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma (Pembro-FLASH) Not yet recruiting DEU 0
NCT04114136 Phase II Nivolumab Metformin + Nivolumab Pembrolizumab Metformin + Pembrolizumab Pembrolizumab + Rosiglitazone Nivolumab + Rosiglitazone Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies Recruiting USA 0
NCT06157151 Phase II Pembrolizumab + PRGN-2009 Pembrolizumab PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer Recruiting USA 0
NCT03358472 Phase III Pembrolizumab Carboplatin + Fluorouracil Epacadostat + Pembrolizumab Cetuximab + Cisplatin Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) Active, not recruiting USA | ITA | GBR | ESP | CAN | AUT | AUS 7
NCT03546582 Phase II Pembrolizumab SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma (KEYSTROKE) Recruiting USA | CAN 0
NCT04453046 Phase I Pembrolizumab Hemopurifier Plus Pembrolizumab in Head and Neck Cancer Terminated USA 0
NCT04032418 Phase II Pembrolizumab Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT03833167 Phase III Pembrolizumab Pembrolizumab Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630) Active, not recruiting USA | NZL | ITA | GBR | FRA | ESP | DEU | CAN | AUS 15
NCT02998268 Phase II Pembrolizumab Carboplatin + Paclitaxel Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma Active, not recruiting USA 0
NCT04811027 Phase II Eftilagimod alpha + Pembrolizumab Pembrolizumab Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC (TACTI-003) Active, not recruiting USA | GBR | ESP | DEU | BEL | AUS 3
NCT03379441 Phase II Pembrolizumab Pembrolizumab (MK-3475) as Maintainance in Treated Patients With Unresectable Stage III NSCLC (MP-LALC) Unknown status ITA 0
NCT02311582 Phase Ib/II Pembrolizumab MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas Completed USA 0
NCT02085070 Phase II Pembrolizumab MK-3475 in Melanoma and NSCLC Patients With Brain Metastases Completed USA 0
NCT02837042 Phase II Pembrolizumab Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma Terminated USA 0
NCT02693535 Phase II Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Ipilimumab + Nivolumab Palbociclib Afatinib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Crizotinib Abemaciclib Sunitinib Olaparib TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR) Recruiting USA 0
NCT03311308 Phase I Metformin + Pembrolizumab Pembrolizumab A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma Recruiting USA 0
NCT05463848 Phase II Olaparib + Pembrolizumab + Temozolomide Pembrolizumab Surgical Pembro +/- Olaparib w TMZ for rGBM Recruiting USA 0
NCT05933577 Phase III Pembrolizumab mRNA-4157 + Pembrolizumab A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001) Recruiting USA | NZL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 13
NCT06004336 Phase II Pembrolizumab A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs) Recruiting USA 0
NCT06054477 Phase Ib/II ALE.C04 + Pembrolizumab ALE.C04 Pembrolizumab Study of ALE.C04 in Patients With Head and Neck Cancer Recruiting USA | ITA | ESP | CAN 2
NCT02882282 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias Active, not recruiting USA 0
NCT03374488 Phase III Epacadostat + Pembrolizumab Pembrolizumab Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS 9
NCT02411656 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy Active, not recruiting USA 0
NCT02886585 Phase II Pembrolizumab Pembrolizumab In Central Nervous System Metastases Active, not recruiting USA 0
NCT05071014 Phase I Pembrolizumab A Study of Pembrolizumab and Cryoablation in People With Mesothelioma Completed USA 0
NCT02493361 Phase II Pembrolizumab IL-12 gene Trial of pIL-12/MK-3475 in Metastatic Melanoma Completed USA 0
NCT06164275 Phase II Pembrolizumab Dacarbazine + Doxorubicin + Vinblastine Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma Recruiting USA 0
NCT04157985 Phase III Nivolumab Ipilimumab Pembrolizumab Atezolizumab Evaluation of the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors Recruiting USA 0
NCT02563002 Phase III Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Pembrolizumab Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) Completed 0
NCT03504163 Phase II Pembrolizumab Pembrolizumab (MK-3475) as First-line Therapy for Carcinoma in Situ (Tis) Non-Muscle-Invasive Bladder Cancer Recruiting USA 0
NCT02559687 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180) Completed 0
NCT03727061 Phase II Cisplatin + Fluorouracil Carboplatin + Fluorouracil Pembrolizumab Cetuximab Nivolumab Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer Recruiting USA 0
NCT02437071 Phase II Pembrolizumab Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients Active, not recruiting USA 0
NCT02599779 Phase II Pembrolizumab A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients Completed CAN 0
NCT02343952 Phase II Pembrolizumab Consolidation Pembrolizumab (MK-3475), Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC Completed USA 0
NCT03259867 Phase II Nivolumab Pembrolizumab Combination of TATE and PD-1 Inhibitor in Liver Cancer Recruiting USA 0
NCT03382899 Phase II Pegilodecakin + Pembrolizumab Pembrolizumab Study of AM0010 With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer (Cypress 1)mall Cell Lung Cancer (Cypress 1) Terminated USA 0
NCT04638582 Phase II Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC) Recruiting CAN 0
NCT03996473 Phase Ib/II Pembrolizumab Pembrolizumab + Radium Ra 223 dichloride Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases Terminated USA | NLD | ESP | BEL 0
NCT02408042 Phase Ib/II Rituximab Carboplatin + Etoposide + Ifosfamide Pembrolizumab Brentuximab vedotin Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) Withdrawn USA 0
NCT04340258 Phase Ib/II Pembrolizumab Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC Active, not recruiting USA 0
NCT03695471 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides Active, not recruiting USA 0
NCT03142334 Phase III Pembrolizumab Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS 12
NCT01953692 Phase I Pembrolizumab A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013) Completed 0
NCT03347617 Phase II Pembrolizumab Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Brain Tumors From Melanoma and Glioblastoma Active, not recruiting USA 0
NCT02620423 Phase I Gemcitabine Fluorouracil Irinotecan Pelareorep Leucovorin Pembrolizumab Study of Pembrolizumab With REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma Completed USA 0
NCT04317534 Phase II Pembrolizumab Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm Recruiting USA 0
NCT03757689 Phase II Pembrolizumab Neoadjuvant PD-1 Blockade in Patients With Stage IIB/C Melanoma Recruiting USA 0
NCT02399371 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Malignant Mesothelioma Active, not recruiting USA 0
NCT04323202 Phase I Pembrolizumab Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N Active, not recruiting USA 0
NCT02579863 Phase III Pembrolizumab Dexamethasone Lenalidomide Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185) Terminated 0
NCT06307431 Phase II Pembrolizumab mRNA-4157 + Pembrolizumab A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004) Recruiting USA | CAN | AUS 2
NCT02451930 Phase I Necitumumab Pembrolizumab A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC Completed USA | FRA | ESP 1
NCT04129515 Phase Ib/II Pembrolizumab NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis Not yet recruiting USA 0
NCT05217446 Phase II Pembrolizumab Cetuximab + Encorafenib + Pembrolizumab A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer (SEAMARK) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 6
NCT03419130 Phase II Pembrolizumab Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer Withdrawn USA 0
NCT02642809 Phase I Pembrolizumab Pembrolizumab With Locally Delivered Radiation Therapy for the Initial Treatment of Metastatic Esophageal Cancers Completed USA 0
NCT03092323 Phase II Pembrolizumab A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032) Active, not recruiting USA | ITA | CAN | AUS 0
NCT02628067 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Recruiting USA | NLD | ITA | FRA | ESP | DEU | CAN | AUS 15
NCT03385226 Phase II Pembrolizumab A Trial Assessing the Effect of Pembrolizumab Combined With Radiotherapy in Patients With Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS) (PORT) Active, not recruiting GBR 0
NCT02959463 Phase I Pembrolizumab Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma Active, not recruiting USA 0
NCT02339324 Phase I Interferon alpha-2b Pembrolizumab Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b Completed USA 0
NCT05420948 Phase II Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer Recruiting USA 0
NCT02728830 Phase I Pembrolizumab A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers Completed USA 0
NCT04827862 Phase II Pembrolizumab RADVAX for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy Recruiting USA 0
NCT02853344 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427) Completed 0
NCT05488366 Phase I Pembrolizumab Immunotherapy Combined With Radiotherapy for Metastatic Sarcoma Recruiting USA 0
NCT03287050 Phase I Pembrolizumab Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma Terminated USA 0
NCT02263508 Phase Ib/II Pembrolizumab Talimogene laherparepvec MK-3475 With or Without Talimogene Laherparepvec in Unresected Melanoma Terminated USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 10
NCT04793815 FDA approved Pembrolizumab Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE) Completed CAN 0
NCT02581982 Phase II Pembrolizumab Paclitaxel Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer Completed USA 0
NCT02609503 Phase II Pembrolizumab Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin Completed USA 0
NCT02382406 Phase Ib/II Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC Terminated USA 0
NCT03924895 Phase III Pembrolizumab Perioperative Pembrolizumab (MK-3475) Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 19
NCT04875195 Phase II Pembrolizumab A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68) Active, not recruiting USA | ITA | FRA | CAN 7
NCT03274661 Phase II Pembrolizumab Pembrolizumab Activity in Patients With HR Competent and Deficient Tumors Completed USA 0
NCT05814666 Phase II Pembrolizumab Danvatirsen + Pembrolizumab Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC (PEMDA-HN) Recruiting USA 1
NCT05172258 Phase II Ipatasertib + Pembrolizumab Pembrolizumab Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck Recruiting USA 0
NCT04370509 Phase II Pembrolizumab Axitinib + Pembrolizumab Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery Recruiting USA 0
NCT02673333 Phase II Pembrolizumab Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma Active, not recruiting USA 0
NCT02437370 Phase I Pembrolizumab Gemcitabine Docetaxel Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer Completed USA 0
NCT02977468 Phase I Pembrolizumab Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer (Pembro/IORT) Recruiting USA 0
NCT04220866 Phase II Pembrolizumab + Ulevostinag Pembrolizumab Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002) Completed USA | GBR | FRA | ESP | AUT | AUS 4
NCT05075122 Phase II Pembrolizumab + Sargramostim + UV1 Telomerase peptide vaccine Pembrolizumab Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab (FOCUS) Recruiting DEU 0
NCT06116578 Phase II Pembrolizumab Olaparib + Pembrolizumab Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab (NeoSarc) Not yet recruiting FRA 0
NCT02707666 Phase I Pembrolizumab Cisplatin + Pemetrexed Disodium A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma Recruiting USA 0
NCT04547504 Phase III Cisplatin + Pembrolizumab + Pemetrexed Disodium Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 >= 50 % (PERSEE) Recruiting FRA 0
NCT04295863 Phase I Nivolumab Pembrolizumab Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers Recruiting USA 0
NCT03844750 Phase II Fluorouracil + Leucovorin + Oxaliplatin Pembrolizumab Pembrolizumab After Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Who Are Undergoing Liver Surgery Recruiting USA 0
NCT02434354 Phase I Pembrolizumab A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma Completed USA 0
NCT03233724 Phase Ib/II Pembrolizumab Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for, Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas Terminated USA 0
NCT04736173 Phase III Zimberelimab Carboplatin + Paclitaxel + Pemetrexed Disodium AB154 + Zimberelimab Pembrolizumab Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer (ARC-10) Active, not recruiting USA | FRA 16
NCT02483247 Phase Ib/II Paclitaxel Doxorubicin Capecitabine Nivolumab Sunitinib Pembrolizumab Amcasertib A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer Completed USA | CAN 0
NCT02736266 Phase II Pembrolizumab Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma Completed ITA 0
NCT02499952 Phase II Pembrolizumab Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors Terminated USA 0
NCT02453594 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087) Completed 0
NCT04808999 Phase II Pembrolizumab Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC) Active, not recruiting USA 0
NCT04016116 Phase II Pembrolizumab + Ruxolitinib Pembrolizumab Dual PD-1 and JAK2 Inhibition in Hematological Malignancies Withdrawn USA 0
NCT02256436 Phase III Pembrolizumab A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045) Completed 0
NCT03765918 Phase III Pembrolizumab Cisplatin + Pembrolizumab Cisplatin Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) Active, not recruiting USA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 15
NCT02335424 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52) Completed 0
NCT02089685 Phase Ib/II Ipilimumab Peginterferon alfa-2b Pembrolizumab Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) Completed 0
NCT02841748 Phase II Pembrolizumab A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study Active, not recruiting USA 0
NCT02852655 Phase 0 Pembrolizumab A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma Completed USA 0
NCT05204290 Phase I Pembrolizumab A Pilot Study of Combined Decompressive Spine Radiosurgery and Pembrolizumab Recruiting USA 0
NCT03793179 Phase III Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Pemetrexed Disodium Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer Active, not recruiting USA | CAN 1
NCT02289209 Phase II Pembrolizumab Reirradiation With MK-3475 in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck Active, not recruiting USA 0
NCT02489357 Phase I Degarelix Pembrolizumab Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer Completed USA 0
NCT06086288 Phase II Pembrolizumab Cisplatin + Etoposide + Pembrolizumab Carboplatin + Etoposide + Pembrolizumab Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naive Advanced meRkel Cell cArcinoma (MCC) (PANDORA) Not yet recruiting ITA 0
NCT03217071 Phase II Pembrolizumab Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer Completed USA 0
NCT03051672 Phase II Pembrolizumab Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC Terminated USA 0
NCT02535247 Phase II Pembrolizumab Study of MK-3475 in Relapsed or Refractory Peripheral T-cell Non-Hodgkin Lymphoma Terminated USA 0
NCT03553836 Phase III Pembrolizumab Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 7
NCT05341349 Phase I Ipilimumab + Nivolumab Pembrolizumab Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases Recruiting USA 0
NCT02407171 Phase Ib/II Pembrolizumab Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC Completed USA 0
NCT02635360 Phase II Cisplatin Pembrolizumab Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer Unknown status USA 0
NCT06005818 Phase II Pembrolizumab Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC) (MRD GATE RCC) Recruiting USA 0
NCT04637594 Phase III Durvalumab Nivolumab Atezolizumab Avelumab Pembrolizumab Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy Active, not recruiting USA 0
NCT03631706 Phase II Bintrafusp alfa Pembrolizumab M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) Active, not recruiting USA | NLD | ITA | FRA | ESP | DEU | CAN | BEL 10
NCT04128696 Phase III Pembrolizumab GSK3359609 + Pembrolizumab Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (INDUCE-3) Terminated USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS 17
NCT03244384 Phase III Pembrolizumab Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer Active, not recruiting USA 1
NCT02555657 Phase III Pembrolizumab Eribulin Gemcitabine Vinorelbine Capecitabine Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) Completed 0
NCT03291353 Phase 0 Pembrolizumab Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia Withdrawn USA 0
NCT02678572 Phase III Dacarbazine Ipilimumab Melphalan Pembrolizumab Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma Completed USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT 1
NCT02899793 Phase II Pembrolizumab Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer Active, not recruiting USA 0
NCT03267888 Phase I Pembrolizumab Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma Completed USA 0
NCT06268613 Phase I Pembrolizumab A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy Recruiting ESP 3
NCT05852223 Phase II Pembrolizumab Pembrolizumab in High-risk Thyroid Cancer (NePenThe) Recruiting ITA 0
NCT06180733 Phase II Pembrolizumab Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer (PAM-II) Recruiting NLD 0
NCT02684292 Phase III Brentuximab vedotin Pembrolizumab Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) Active, not recruiting 0
NCT04009967 Phase II Pembrolizumab Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning (PICT-01) Recruiting CAN 0
NCT03070392 Phase II Dacarbazine Ipilimumab Pembrolizumab Tebentafusp Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 4
NCT02971956 Phase II Pembrolizumab A Phase II Study of Pembrolizumab in Refractory Advanced Esophageal Cancer Completed USA 0
NCT03316573 Phase II Pembrolizumab A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas Suspended USA 0
NCT03311672 Phase II Pembrolizumab T-Cell PET Imaging With [18F]F-AraG in Lung Cancer Withdrawn 0
NCT03783078 Phase III Pembrolizumab Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913) Completed USA | NZL | ITA | FRA | ESP | CAN | AUS 1
NCT04931979 Phase II Pembrolizumab SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical Prostatectomy (Pembro-SRT) Recruiting DEU 0
NCT04746924 Phase III Tislelizumab BGBA1217 + Tislelizumab Pembrolizumab A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer Recruiting USA | FRA | DEU 6
NCT04098068 Phase II Pembrolizumab Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D) Active, not recruiting USA 0
NCT05352672 Phase III Cemiplimab Cemiplimab + Fianlimab Pembrolizumab Clinical Study of Fianlimab in Combination With Cemiplimab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 13
NCT03136055 Phase II Irinotecan + Pembrolizumab Paclitaxel + Pembrolizumab Pembrolizumab Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas Completed USA 0
NCT02591654 Phase I Pembrolizumab MRI/PET Imaging to Assess Response to Pembrolizumab in Metastatic Melanoma Terminated USA 0
NCT03035331 Phase Ib/II Pembrolizumab Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT05608291 Phase III Pembrolizumab Cemiplimab + Fianlimab A Study to Evaluate the Superiority of the Fianlimab and Cemiplimab Combination Compared to Pembrolizumab in Adult and Adolescent Patients With Completely Resected High-Risk Skin Cancer Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 13
NCT06366451 Phase I AZD2936 Pembrolizumab AZD7789 MEDI5752 PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC Recruiting USA 0
NCT03498612 Phase II Pembrolizumab Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases Active, not recruiting USA 0
NCT05215340 Phase III Pembrolizumab Datopotamab deruxtecan + Pembrolizumab Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 17
NCT02892201 Phase II Pembrolizumab Pembrolizumab in HNSCC With Residual Disease After Radiation Terminated USA 0
NCT04380636 Phase III Carboplatin Pemetrexed Disodium Pembrolizumab Cisplatin Durvalumab Etoposide Olaparib + Pembrolizumab Paclitaxel Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN 19
NCT04946370 Phase Ib/II Pembrolizumab 225Ac-J591 + Pembrolizumab Maximizing Responses to Anti-PD1 Immunotherapy With PSMA-targeted Alpha Therapy in mCRPC Recruiting USA 0
NCT06155279 Phase II Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study) (CHIMERA) Not yet recruiting ITA 0
NCT03255018 Phase II Pembrolizumab Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extra-Nodal Diffuse Large B-cell Lymphomas Completed USA 0
NCT03087019 Phase II Pembrolizumab Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma Completed USA 0
NCT04134325 Phase I Nivolumab Pembrolizumab Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma Recruiting USA 0
NCT04565496 Phase II Pembrolizumab Phase 2 Study of Neoadjuvant PEMbrolizumab Before Radical PROstatectomy in High-risk Prostate Cancer Patients (PEM-PRO) Unknown status ITA 0
NCT02337686 Phase II Pembrolizumab Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma Active, not recruiting USA 0
NCT03804944 Phase II CDX-301 CDX-301 + Pembrolizumab Pembrolizumab Converting HR+ Breast Cancer Into an Individualized Vaccine (CBCV) Recruiting USA 0
NCT02331251 Phase Ib/II Vinorelbine Pembrolizumab Irinotecan Doxorubicin Gemcitabine Docetaxel Nab-paclitaxel Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) Terminated USA 0
NCT04895722 Phase II MK-4280A MK-7684A MK-1308A MK-4830 + Pembrolizumab Pembrolizumab Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL 13
NCT02644369 Phase II Pembrolizumab Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors (INSPIRE) Active, not recruiting CAN 0
NCT03248570 Phase II Pembrolizumab Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects Completed USA 0
NCT02603887 Phase I Pembrolizumab Pembrolizumab for Smoldering Multiple Myeloma (SMM) Active, not recruiting USA 0
NCT02641093 Phase II Cisplatin Pembrolizumab Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma Active, not recruiting USA 0
NCT03126630 Phase Ib/II Pembrolizumab Anetumab ravtansine + Pembrolizumab Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma Active, not recruiting USA | CAN 0
NCT05496036 Phase II Pembrolizumab Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma (MCC) Recruiting USA 0
NCT04605614 Phase I Pembrolizumab 64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression Withdrawn 0
NCT01876511 Phase II Pembrolizumab Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors Completed USA 0
NCT06246968 Phase I Pembrolizumab A Study of Pembrolizumab and Cryoablation in People With Breast Cancer Recruiting USA 0
NCT03976362 Phase III Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Olaparib + Pembrolizumab A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008) Active, not recruiting USA | NZL | GBR | FRA | ESP | DEU | CAN | AUT | AUS 11
NCT03425643 Phase III Cisplatin + Pemetrexed Disodium Cisplatin + Gemcitabine + Pembrolizumab Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Gemcitabine Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 16
NCT03898180 Phase III Lenvatinib + Pembrolizumab Pembrolizumab Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS 11
NCT02819518 Phase III Paclitaxel Pembrolizumab Nab-paclitaxel Carboplatin + Gemcitabine Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) Completed 0
NCT05007106 Phase II MK-7684A + Paclitaxel Cisplatin + Fluorouracil + MK-7684A Pembrolizumab Lenvatinib + MK-7684A MK-7684A MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) Recruiting USA | NLD | ITA | FRA | ESP | DEU | CAN 8
NCT05064280 Phase II Lenvatinib Pembrolizumab Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases Recruiting USA 0
NCT06190249 Phase I Cyclophosphamide + Fludarabine Lifileucel Pembrolizumab Aldesleukin Mesna Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma Not yet recruiting USA 0
NCT02359565 Phase I Pembrolizumab Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas or Diffuse Intrinsic Pontine Gliomas Recruiting USA | CAN 0
NCT05727904 Phase III Lifileucel + Pembrolizumab Pembrolizumab Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. Recruiting USA | NLD | ITA | FRA | ESP | CAN | AUS 1
NCT03390504 Phase III Pembrolizumab Erdafitinib Docetaxel + Vinflunine A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 16
NCT03486873 Phase III Pembrolizumab Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) Recruiting USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 37
NCT02919969 Phase II Pembrolizumab Pembrolizumab in Refractory Metastatic Anal Cancer Completed USA 0
NCT04892472 Phase II Pembrolizumab EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (KEYNOTE B36) Recruiting USA 0
NCT02708641 Phase II Pembrolizumab A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients 60 With AML Completed USA 0
NCT04089904 Phase II Pembrolizumab Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma Terminated USA 0
NCT03924869 Phase III Pembrolizumab Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Medically Inoperable Stage I or IIA Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867) Active, not recruiting USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS 13
NCT03753659 Phase II Pembrolizumab IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC) Active, not recruiting DEU 0
NCT02054806 Phase I Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28) Completed 0
NCT03325166 Phase II Pembrolizumab Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases Terminated USA 0
NCT03319745 Phase II Pembrolizumab A Window of Opportunity Study of Pembrolizumab in Patients With Bladder Cancer Undergoing Radical Cystectomy Completed USA 0
NCT04657991 Phase III Pembrolizumab Binimetinib + Encorafenib + Pembrolizumab A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma Active, not recruiting USA | NZL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT 17
NCT02755272 Phase II Pembrolizumab Carboplatin + Gemcitabine A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer Active, not recruiting USA 0
NCT02650999 Phase Ib/II Pembrolizumab Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas Completed USA 0
NCT01822652 Phase I Cyclophosphamide Fludarabine Pembrolizumab 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN Active, not recruiting USA 0
NCT02179918 Phase I Utomilumab Pembrolizumab A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036) Completed USA 0
NCT03725059 Phase III Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Cyclophosphamide + Epirubicin + Paclitaxel Pembrolizumab Cyclophosphamide + Doxorubicin + Paclitaxel Cyclophosphamide + Epirubicin + Paclitaxel + Pembrolizumab Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) Active, not recruiting USA | NZL | GBR | FRA | ESP | DEU | CAN | BEL | AUS 15
NCT05406713 Phase II Pembrolizumab Pembrolizumab in MIBC Recruiting USA 0
NCT02595866 Phase I Pembrolizumab Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms Active, not recruiting USA 0
NCT02954874 Phase III Pembrolizumab Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Active, not recruiting USA | CAN 1
NCT02521870 Phase I Pembrolizumab SD-101 A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma Terminated USA | NZL | DEU | AUS 0
NCT02880345 Phase 0 Pembrolizumab RADVAX: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy Withdrawn USA 0
NCT04046133 Phase I Pembrolizumab Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus (CORINTH) Unknown status GBR 1
NCT06036836 Phase II Lenvatinib + Pembrolizumab Lenvatinib + MK-4280A MK-4280A Pembrolizumab Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Recruiting USA | NLD | FRA | CAN | AUS 3
NCT05092360 Phase III Pembrolizumab ALKS 4230 Topotecan Paclitaxel Pegylated liposomal doxorubicin Gemcitabine ALKS 4230 + Pembrolizumab Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab (ARTISTRY-7) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 5
NCT04166734 Phase I Pembrolizumab Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma (MESO-PRIME) Terminated GBR 0
NCT06366347 Phase II Pembrolizumab Abemaciclib + Letrozole ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab Not yet recruiting USA 0
NCT05197322 Phase II Pembrolizumab NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer (NEOPRISM-CRC) Recruiting GBR 0
NCT04274907 Phase I Pembrolizumab + Venetoclax Pembrolizumab A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression Terminated USA 0
NCT03302234 Phase III Pembrolizumab Ipilimumab + Pembrolizumab Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 16
NCT02557321 Phase Ib/II PV-10 Pembrolizumab PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma Active, not recruiting USA 0
NCT02906332 Phase II Pembrolizumab Dexamethasone Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM) Terminated USA 0
NCT02362035 Phase Ib/II Acalabrutinib Pembrolizumab ACP-196 in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (KEYNOTE145) Active, not recruiting USA 0
NCT03309878 Phase Ib/II Pembrolizumab Mogamulizumab + Pembrolizumab Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Lymphomas Completed USA 0
NCT02775851 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT06066333 Phase II Pembrolizumab Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma Recruiting USA 0
NCT02359851 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Advanced Uveal Melanoma Terminated USA 0
NCT03307759 Phase I Pembrolizumab Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma (SABRseq) Completed CAN | AUS 0
NCT02658097 Phase II Pembrolizumab A Randomized Two Arm Phase II Trial of Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC Completed USA 0
NCT02142738 Phase III Cisplatin Paclitaxel Carboplatin Gemcitabine Pembrolizumab Pemetrexed Disodium Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) Completed 0
NCT06077760 Phase III mRNA-4157 + Pembrolizumab Pembrolizumab A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) Recruiting USA | NZL | FRA | ESP | CAN | AUS 9
NCT02331368 Phase II Lenalidomide Melphalan Pembrolizumab Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma Completed USA 0
NCT02621151 Phase II Pembrolizumab Gemcitabine Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder Active, not recruiting USA 0
NCT02546986 Phase II Azacitidine + Pembrolizumab Pembrolizumab Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer Active, not recruiting USA | ITA | FRA | ESP | DEU 1
NCT05025813 Phase II Pembrolizumab Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma (DESQUAMATE) Recruiting AUS 0
NCT03166254 Phase I Pembrolizumab Combination of a Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab in Non-Small Cell Lung Cancer Withdrawn 0
NCT03189186 Phase I Pembrolizumab Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas Withdrawn USA 0
NCT04134559 Phase II Pembrolizumab Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma Recruiting USA 0
NCT05980598 Phase II Pembrolizumab + TransCon TLR7/8 Agonist TransCon IL-2 beta/gamma + TransCon TLR7/8 Agonist Pembrolizumab TransCon (TC) TLR7/8 Agonist, TC IL-2 beta/gamma, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma (BelieveIT-201) Recruiting USA | ITA | ESP | DEU 3
NCT03582475 Phase I Etoposide Carboplatin + Docetaxel + Etoposide + Pembrolizumab Cisplatin + Etoposide + Pembrolizumab Pembrolizumab Carboplatin + Etoposide + Pembrolizumab Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate Completed USA 0
NCT03406858 Phase II Pembrolizumab Pembrolizumab and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer Completed USA 0
NCT04069273 Phase II Paclitaxel + Ramucirumab Paclitaxel + Pembrolizumab + Ramucirumab Pembrolizumab Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma (SEQUEL) (SEQUEL) Recruiting USA 0
NCT04475939 Phase III Pembrolizumab Niraparib + Pembrolizumab Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo and Pembrolizumab as Maintenance Therapy (ZEAL-1L) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUS 18
NCT03072160 Phase II Pembrolizumab Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer Completed USA 0
NCT03568058 Phase I Pembrolizumab Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers Active, not recruiting USA 0
NCT03313804 Phase II Pembrolizumab Atezolizumab Nivolumab Priming Immunotherapy in Advanced Disease With Radiation Active, not recruiting USA 0
NCT04929041 Phase II Pembrolizumab Nab-paclitaxel Ipilimumab Paclitaxel Nivolumab Pemetrexed Disodium Carboplatin Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative Recruiting USA 0
NCT06377566 Phase II Brentuximab vedotin + Dacarbazine + Doxorubicin + Vinblastine Gemcitabine Dacarbazine Doxorubicin Pembrolizumab Brentuximab vedotin Vinorelbine Vinblastine A Study of BV-AVD in People With Bulky Hodgkin Lymphoma Recruiting USA 0
NCT02358031 Phase III Cetuximab Pembrolizumab Fluorouracil Carboplatin Cisplatin A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) Completed 0
NCT02949219 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT03574220 Phase I Pembrolizumab Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung Cancer Withdrawn 0
NCT05879120 Phase II Pembrolizumab Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma Not yet recruiting USA 0
NCT02638090 Phase Ib/II Pembrolizumab Vorinostat Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) Active, not recruiting USA 0
NCT03990961 Phase II Pembrolizumab Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL) Recruiting USA 0
NCT03325101 Phase Ib/II Pembrolizumab Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery Active, not recruiting USA 0
NCT04569461 Phase II Pembrolizumab Trimodality Approach to Localized Prostate Cancer: Pembrolizumab, ADT, and SBRT Followed by Prostatectomy (TALON) Not yet recruiting USA 0
NCT05633654 Phase III Pembrolizumab + Sacituzumab govitecan-hziy Capecitabine + Pembrolizumab Pembrolizumab Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05) Recruiting USA 0
NCT02332668 Phase Ib/II Pembrolizumab A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) Recruiting USA | NLD | ITA | GBR | FRA | DEU 4
NCT02359019 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Extensive Stage Small Cell Lung Cancer After Completion of Combination Chemotherapy Completed USA 0
NCT05155254 Phase III IO102-IO103 + Pembrolizumab Pembrolizumab IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUS 7
NCT03430700 Phase II Pembrolizumab Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer (PROMPT) Active, not recruiting GBR 0
NCT02858869 Phase 0 Pembrolizumab Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases Completed USA 0
NCT03304639 Phase II Pembrolizumab Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer Active, not recruiting USA 0
NCT02688608 Phase II Pembrolizumab Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Completed USA 0
NCT05119296 Phase II Pembrolizumab Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer Recruiting USA 0
NCT02422381 Phase Ib/II Gemcitabine Pembrolizumab MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting USA 0
NCT03341143 Phase II Pembrolizumab Fecal Microbiota Transplant (FMT) in Melanoma Patients Active, not recruiting USA 0
NCT04897022 Phase I Pembrolizumab A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma Recruiting USA 0
NCT03237572 Phase I Pembrolizumab Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer (Breast-48) Terminated USA 0
NCT04214249 Phase II Cytarabine + Daunorubicin Cytarabine Cytarabine + Idarubicin Pembrolizumab Cytarabine + Daunorubicin + Pembrolizumab Cytarabine + Pembrolizumab Cytarabine + Idarubicin + Pembrolizumab BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia Recruiting USA 0
NCT04622007 Phase II Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium + Tomivosertib Pembrolizumab Pembrolizumab + Tomivosertib Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) (KICKSTART) Active, not recruiting USA | AUS 1
NCT04082572 Phase II Pembrolizumab Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers Active, not recruiting USA 0
NCT03407170 Phase II Pembrolizumab Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161) Terminated USA 0
NCT03225664 Phase Ib/II Pembrolizumab Pembrolizumab + Trametinib BATTLE-2 Program - A Biomarker-Integrated Targeted Therapy in Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting USA 0
NCT05185739 Phase II Lenvatinib + Pembrolizumab Lenvatinib Pembrolizumab Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC) (PRIMER-1) Recruiting GBR 0
NCT02775435 Phase III Carboplatin + Nab-paclitaxel Pembrolizumab Carboplatin + Paclitaxel A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) Completed 0
NCT05589818 Phase II Pembrolizumab Pembrolizumab for Advanced NSCLC and PS 2-3 Recruiting USA 0
NCT05034536 Phase II Pembrolizumab Infliximab + Pembrolizumab Pembrolizumab + Infliximab for Metastatic Melanoma Recruiting USA 0
NCT02621021 Phase II Pembrolizumab Cyclophosphamide Fludarabine Aldesleukin A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab Suspended USA 0
NCT05846659 Phase II Nivolumab IMSA101 + Nivolumab IMSA101 + Pembrolizumab Pembrolizumab Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies Recruiting USA 0
NCT03007732 Phase II Pembrolizumab + SD-101 Pembrolizumab Pembrolizumab in Combination With Intratumoral SD-101 Therapy Active, not recruiting USA 0
NCT03099564 Phase I Pembrolizumab Pembrolizumab Plus Y90 Radioembolization in HCC Subjects Active, not recruiting USA 0
NCT03486197 Phase II Pembrolizumab Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma Terminated USA 0
NCT02255097 Phase II Pembrolizumab Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055) Completed 0
NCT04139317 Phase II Capmatinib + Pembrolizumab Pembrolizumab Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1 >= 50% Terminated NLD | ITA | FRA | ESP | DEU | CAN | BEL | AUS 8
NCT03197467 Phase II Pembrolizumab Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer (NEOMUN) Completed DEU 0
NCT03295227 Phase I Pembrolizumab Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma Recruiting USA 0
NCT02337491 Phase II Pembrolizumab Bevacizumab + Pembrolizumab Pembrolizumab +/- Bevacizumab for Recurrent GBM Completed USA 0
NCT02939651 Phase II Pembrolizumab A Study of Pembrolizumab in Patients With Neuroendocrine Tumors Completed USA 0
NCT03331562 Phase II Pembrolizumab Paricalcitol + Pembrolizumab A SU2C Catalyst Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer Completed USA 0
NCT02600949 Phase I Pembrolizumab Peptide Vaccine in Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma Recruiting USA 0
NCT03634241 Phase II Pembrolizumab Pembrolizumab in Treating Participants With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules Recruiting USA 0
NCT05539365 Phase Ib/II Pembrolizumab Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer Not yet recruiting USA 0
NCT02267603 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer Completed USA 0
NCT02351739 Phase II Pembrolizumab Acalabrutinib Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum-refractory Metastatic Bladder Cancer Completed USA 0
NCT02581943 Phase II Paclitaxel Pembrolizumab Carboplatin Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer Completed USA 0
NCT02318771 Phase I Pembrolizumab Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer Completed USA 0
NCT04454489 Phase II Pembrolizumab Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition Recruiting USA 0
NCT04207086 Phase II Lenvatinib + Pembrolizumab Pembrolizumab A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma (Neo PeLe) Active, not recruiting AUS 0
NCT03383094 Phase II Pembrolizumab Cisplatin + Radiotherapy Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer Recruiting USA 0
NCT04659811 Phase II Pembrolizumab Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma Recruiting USA 0
NCT03891979 FDA approved Ciprofloxacin Metronidazole Pembrolizumab Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma Withdrawn USA 0
NCT03179917 Phase II Pembrolizumab Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma Recruiting USA 0
NCT04305054 Phase Ib/II Pembrolizumab + Vibostolimab Pembrolizumab Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B) Recruiting USA | ITA | FRA | ESP | AUS 9
NCT03286114 Phase I Pembrolizumab Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab Terminated USA 0
NCT02658019 Phase II Pembrolizumab Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma Completed USA 0
NCT04214067 Phase III Pembrolizumab Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer Active, not recruiting USA 1
NCT03210662 Phase II Pembrolizumab Pembrolizumab and Fractionated External Beam Radiotherapy (EBRT) in Patients With Non-Hodgkin Lymphoma (NHL) Active, not recruiting USA 0
NCT05709821 Phase Ib/II Pembrolizumab IMM60 IMM60 + Pembrolizumab IMM60 and Pembrolizumab in Melanoma and NSCLC Terminated USA | GBR | ESP 0
NCT03273153 Phase III Pembrolizumab Atezolizumab + Cobimetinib A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma Terminated USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUS 6
NCT03366844 Phase Ib/II Pembrolizumab Breast Cancer Study of Preoperative Pembrolizumab + Radiation Active, not recruiting USA 0
NCT04375956 Phase II Pembrolizumab Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients (MITO 27) Recruiting ITA 0
NCT02362594 Phase III Pembrolizumab Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054) Active, not recruiting 0
NCT03449238 Phase Ib/II Pembrolizumab Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients Recruiting USA 0
NCT02009449 Phase I Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors Active, not recruiting USA 0
NCT06096844 Phase III Nab-paclitaxel Pembrolizumab Carboplatin Pemetrexed Disodium Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial Recruiting USA 0
NCT03878524 Phase I Oxaliplatin Palbociclib Vemurafenib Sirolimus Tretinoin Celecoxib Ipilimumab Ruxolitinib Dasatinib Abiraterone Idelalisib Trametinib Imatinib Erlotinib Carboplatin Olaparib Panobinostat Bortezomib Afatinib Fluorouracil Vorinostat Pembrolizumab Leucovorin Enzalutamide Ponatinib Nivolumab Everolimus Sunitinib Cabazitaxel Cabozantinib Lenvatinib Pertuzumab Sorafenib Venetoclax Bevacizumab A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART) Terminated USA 0
NCT02752074 Phase III Epacadostat + Pembrolizumab Pembrolizumab A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma Completed USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 12
NCT03632941 Phase II Pembrolizumab AVX901 + Pembrolizumab AVX901 A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer Active, not recruiting USA 0
NCT03519412 Phase II Pembrolizumab Temozolomide Pembrolizumab + Temozolomide Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status (ARETHUSA) Active, not recruiting ITA 0
NCT04443348 Phase II Pembrolizumab Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) Recruiting USA 0
NCT03515629 Phase III Cemiplimab + Ipilimumab Pembrolizumab REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer Terminated USA | ITA 1
NCT03732950 Phase II Pembrolizumab Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer Active, not recruiting USA 0
NCT02316002 Phase II Pembrolizumab Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer Completed USA 0
NCT04675294 Phase II Evorpacept + Pembrolizumab Pembrolizumab Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) Recruiting USA | NLD | GBR | ESP | CAN | BEL | AUS 2
NCT02830594 Phase II Pembrolizumab Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer Completed USA 0
NCT04738487 Phase III Pembrolizumab MK-7684A Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) Recruiting USA | CAN 21
NCT02324582 Phase I Pembrolizumab MK-3475/BCG in High Risk Superficial Bladder Cancer Unknown status USA 0
NCT03245489 Phase I Pembrolizumab Pembrolizumab in Combination With Anti-platelet Therapy for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Recruiting USA 0
NCT02499835 Phase Ib/II Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer Completed USA 0
NCT05846646 Phase II Pembrolizumab Nivolumab IMSA101 + Nivolumab IMSA101 + Pembrolizumab Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC Recruiting USA 0
NCT04533451 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT02501096 Phase Ib/II Pembrolizumab Lenvatinib Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors Completed USA | ESP 1
NCT02940496 Phase Ib/II Pembrolizumab Pembrolizumab (MK-3475) in Hepatocellular Carcinoma Completed USA 0
NCT02971748 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy Active, not recruiting USA 0
NCT05899608 Phase III Pembrolizumab Ivonescimab Clinical Study of Ivonescimab for First-line Treatment of Metastatic Squamous NSCLC Patients Recruiting USA | CAN 0
NCT02740920 Phase II Pembrolizumab Assessment of Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography (CT) Texture Analysis as a Predictive Biomarker Terminated CAN 0
NCT02560636 Phase I Pembrolizumab Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer (PLUMMB) Recruiting GBR 0
NCT01174121 Phase II Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Recruiting USA 0
NCT02690948 Phase II Pembrolizumab + Vismodegib Pembrolizumab Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer Completed USA 0
NCT03085719 Phase II Pembrolizumab Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN Active, not recruiting USA 0
NCT02818920 Phase II Pembrolizumab Neoadjuvant Pembrolizumab Active, not recruiting USA 0
NCT05059470 Phase II Pembrolizumab IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC Recruiting USA 0
NCT03089606 Phase II Pembrolizumab Pembrolizumab TX-naive Distant Mets Melanoma and Use of AMT (PET) at Baseline as Imaging Biomarker Completed USA 0
NCT04093167 Phase II Pembrolizumab Study of CTDNA Response Adaptive Immuno-Chemotherapy in NSCLC Recruiting USA | CAN 0
NCT03712605 Phase III Pembrolizumab Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer Suspended USA 0
NCT02574533 Phase I Pembrolizumab FANG vaccine Pilot Study of Vigil + Pembrolizumab for Advanced Melanoma Completed USA 0
NCT03506997 Phase II Pembrolizumab Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (PERSEUS1) Recruiting GBR 0
NCT04913025 Phase II Pembrolizumab Nivolumab REduced Frequency ImmuNE Checkpoint Inhibition in Cancers (REFINE) Recruiting GBR 0
NCT03338959 Phase Ib/II Pembrolizumab Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma Completed USA 0
NCT03666325 Phase II Pembrolizumab Cetuximab + Pembrolizumab Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance (I-Tackle) Unknown status ITA 0
NCT02220894 Phase III Carboplatin + Pemetrexed Disodium Carboplatin + Paclitaxel Pembrolizumab Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) Completed 0
NCT02769520 Phase II Pembrolizumab Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck Active, not recruiting USA 0
NCT03727880 Phase II Defactinib + Pembrolizumab Pembrolizumab Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma Recruiting USA 0
NCT03719105 Phase I Pembrolizumab Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Pralatrexate + Prednisone Calaspargase pegol-mknl + Dexamethasone + Etoposide + Ifosfamide + Methotrexate Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma Recruiting USA 0
NCT05204160 Phase II Pembrolizumab Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy Recruiting USA 0
NCT03290079 Phase II Pembrolizumab Pembrolizumab in Advanced Poorly Differentiated and/or High Grade Neuroendocrine Tumors/Carcinomas Active, not recruiting USA 0
NCT04201145 Phase I Pembrolizumab Defactinib + Pembrolizumab Pembrolizumab + Defactinib In Pleural Mesothelioma Withdrawn USA 0
NCT04188951 Phase I Pembrolizumab HFHS-1801-A Pilot Study of Immunotherapy as Consolidation Therapy for Patients With Recurrent Head and Neck Cancer Recruiting USA 0
NCT02787005 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Chemotherapy (MK-3475-199/KEYNOTE-199) Completed 0
NCT05191472 Phase II Pembrolizumab Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies Terminated USA 0
NCT02702414 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) as Monotherapy in Adults With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) Completed 0
NCT04267848 Phase III Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Gemcitabine Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Cisplatin + Gemcitabine + Pembrolizumab Carboplatin + Paclitaxel Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial Recruiting USA 1
NCT02925234 Phase II Palbociclib Ribociclib Lenvatinib Ipilimumab + Nivolumab Trametinib Crizotinib Niraparib Selpercatinib Olaparib Erlotinib Erdafitinib Dabrafenib Dacomitinib Rucaparib Axitinib Panitumumab Pemigatinib Durvalumab Afatinib Entrectinib Tepotinib Alpelisib Atezolizumab + Bevacizumab Alectinib Regorafenib Cobimetinib + Vemurafenib Nilotinib Vismodegib Abemaciclib Sunitinib Nivolumab Cabozantinib Lorlatinib Talazoparib Dabrafenib + Trametinib Pembrolizumab Pertuzumab + Trastuzumab The Drug Rediscovery Protocol (DRUP Trial) (DRUP) Recruiting NLD 0
NCT04708418 Phase II Pembrolizumab Pembrolizumab + Vidutolimod A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy in Patients With Operable Melanoma Suspended USA 0
NCT05565378 Phase II Dostarlimab-gxly Dostarlimab-gxly + EOS-448 Pembrolizumab A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL 14
NCT03867084 Phase III Pembrolizumab Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937) Active, not recruiting USA | NZL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 21
NCT02710396 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Genetic Predictors of Benefit to Pembrolizumab Terminated USA 0
NCT02460198 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164) Completed 0
NCT02575404 Phase I Belapectin Pembrolizumab GR-MD-02 Plus Pembrolizumab in Melanoma Patients Completed USA 0
NCT03867175 Phase III Pembrolizumab Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT03771820 Phase II Pembrolizumab NC-6004 + Pembrolizumab Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen Unknown status 8
NCT05085028 Phase III Pembrolizumab A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (REFINE-Lung) Recruiting GBR 0
NCT02362048 Phase II Acalabrutinib Pembrolizumab ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer Completed USA 0
NCT03322540 Phase II Pembrolizumab Epacadostat + Pembrolizumab Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05) Completed USA | ITA | GBR | ESP | CAN | AUS 12
NCT02632344 Phase II Pembrolizumab Study of Anti-PD-1 Therapy for HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal and/or Pulmonary Involvement Active, not recruiting USA 0
NCT04534205 Phase II BNT113 + Pembrolizumab Pembrolizumab A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 12
NCT02448303 Phase II Acalabrutinib Pembrolizumab Pembrolizumab Alone and In Combination With ACP-196 in Subjects With Advanced Non-small Cell Lung Cancer Completed USA 0
NCT04747054 Phase III Pembrolizumab + Radiotherapy Pembrolizumab Carboplatin + Fluorouracil Cisplatin + Fluorouracil Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers (PembroMetaRT) Recruiting FRA 0
NCT03698019 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery Active, not recruiting USA 0
NCT03432741 Phase I Carfilzomib Daratumumab Obinutuzumab Gemcitabine Trastuzumab Romidepsin Nivolumab Rituximab Belinostat Pembrolizumab Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer Suspended USA 0
NCT02444741 Phase Ib/II Pembrolizumab MK-3475 and Hypofractionated Stereotactic Radiation Therapy in Patients With Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting USA 0
NCT06082167 Phase II Pembrolizumab + XL092 Pembrolizumab Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (STELLAR-305) Recruiting USA 0
NCT03516708 Phase Ib/II Pembrolizumab Epacadostat Capecitabine + Oxaliplatin Epacadostat (INCB024360) and Pembrolizumab Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer Recruiting USA 0
NCT02506153 Phase III Interferon alpha-2b Pembrolizumab High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Active, not recruiting USA | CAN 1
NCT06006923 Phase II Pembrolizumab Pembrolizumab + Regorafenib Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer Not yet recruiting USA 0
NCT02955758 Phase II Pembrolizumab Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer Active, not recruiting USA 0


Additional content available in CKB BOOST